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Immunohistochemical Detection of Survivin in Canine Lymphoma 
 
 
Summary 
 
Survivin is a member of the family of proteins known as ‘inhibitors of apoptosis proteins’.  
Survivin has a role in cellular decisions concerning division and survival and is frequently 
expressed in neoplastic cells.  The aim of the present study was to investigate 
immunohistochemically the expression of survivin in normal canine tissues and in canine 
lymphoma.  A representative range of fetal and adult normal tissues as well as biopsy 
samples from dogs with lymphoma were assembled in tissue arrays. The lymphomas 
were classified according to the revised Kiel and to the revised European American 
Lymphoma – World Health Organization (REAL-WHO) schemes.   Polyclonal and 
monoclonal antisera cross-reactive with canine survivin identified cytoplasmic 
expression of the molecule in a broad range of normal canine cells.  The same reagents 
demonstrated cytoplasmic labelling of more than 5% of cells in all 83 lymphoma samples 
tested with polyclonal antiserum and in 67 of 82 (82%) of samples tested with 
monoclonal antiserum.  Survivin was expressed by a wide range of canine lymphoma 
subtypes, but the expression of this molecule in normal canine tissues must be 
considered if novel therapies targeting survivin are applied to the management of canine 
lymphoma.  
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Introduction 
 
Apoptosis is a phylogenetically conserved mechanism of cell death with roles in 
development and tissue homeostasis (Salvesen and Duckett, 2002). In mammals, it is 
executed through activation of different caspases, which are present in the cell 
cytoplasm as inactive proenzymes. Activation of these molecules can be triggered either 
by external stimuli, which activate the extrinsic apoptotic pathway, or by diverse 
conditions collectively termed ‘cellular stress’, which activate the intrinsic pathway.  
Following stress stimuli, cytochrome c is released from the mitochondrial intermembrane 
space into the cell cytoplasm, where it participates in the assembly of the apoptosome 
and subsequent activation of the initiator caspase-9.  This enzyme cleaves and activates 
downstream caspases that target further cellular substrates for cleavage, eventually 
resulting in cell death (Gerl and Vaux, 2005). 
Inhibitors of apoptosis proteins (IAPs) are a family of proteins that interfere with the 
activation of caspases by various mechanisms (Salvesen and Duckett, 2002).  All 
members of the family possess at least one ‘baculovirus inhibitor of apoptosis repeat’, a 
specific domain that, at least in some of its versions, has been shown to bind and/or 
inactivate caspases.  Increased expression of various IAPs has been reported in several 
types of cancer and is thought to contribute to the phenomenon of resistance to 
apoptosis that is often a feature of the neoplastic process.  Survivin is a member of the 
IAP family with well known functions in the regulation of cell division.  In contrast, its anti-
apoptotic function has long been debated and, only recently, relevant mechanisms have 
been unveiled in tumour cells (Altieri, 2008). In order to inhibit apoptosis, survivin must 
localize to the cytosol and its negative regulatory effect on caspase function appears to 
be indirect (Stauber et al., 2007; Altieri, 2008).  Overexpression of survivin has been 
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reported in a wide range of human cancers, and, similarly to other IAPs, it has been 
shown to negatively influence outcome in many different types of cancer (Stauber et al., 
2007). Based mostly on early data from man, it is frequently claimed that survivin is 
widely expressed  during embryonic development, but is not expressed or only weakly 
expressed in normal adult tissues (Ambrosini et al., 1997; Andersen et al., 2007; Altieri, 
2008).  Some authors concede that survivin is expressed to some extent in adult tissues 
with a high cell turnover including testis, intestinal epithelium and bone marrow 
(Kobayashi et al., 1999).  Evidence that the role of survivin is not restricted to developing 
tissues is emerging, with several reports of its expression in normal adult tissues 
(Fukuda and Pelus, 2006; Lechler et al., 2007). 
Canine survivin is 91.5% homologous to its human counterpart at the amino acid level 
(Uchide et al., 2005).  Immunohistochemical studies have described expression of this 
protein in canine mast cell tumours (Scase et al., 2006), haemangiomas and 
haemangiosarcomas (Murakami et al., 2008), transitional cell carcinomas of the urinary 
bladder (Velando Rankin et al., 2008) and lymphomas (Rebhun et al., 2008).  The 
prognostic significance of this expression remains undetermined.  It has been suggested 
that survivin might be expressed by all canine lymphomas and a negative prognostic 
significance has been attributed to high expression of survivin in B-cell neoplasms 
(Rebhun et al., 2008).  Survivin mRNA has been detected by reverse transcriptase 
polymerase chain reaction (RT-PCR) in the tissue of normal adult dogs including heart, 
lung, liver, stomach, duodenum, colon, spleen, kidney and testis, as well as in various 
tumour tissues (Uchide et al., 2005). Immunohistochemical studies to confirm 
expression of survivin protein have not been performed. 
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The aim of the present study was to establish a reliable method for 
immunohistochemical detection of survivin and to apply this methodology to a detailed 
analysis of expression of survivin protein in normal canine tissues and samples of 
canine lymphoma. 
 
Materials and Methods 
 
Primary Antibodies for Immunohistochemistry 
Two commercially available antibodies raised against full-length human survivin were 
compared in immunohistochemistry (IHC).  The first was a polyclonal, affinity purified 
antibody (survivin-astrocyte marker NB 500-201, Lot Q2; Novus Biologicals Inc., 
Littleton, Colorado) hereafter described as pSurv in this study.  The second was a 
monoclonal antibody (survivin D8: sc-17779, StC Biotechnology Inc., Santa Cruz, 
California), referred to as mSurv in this study.  The specific epitope recognized by the 
monoclonal antibody is unknown.  Lymphomas were immunophenotyped by application 
of polyclonal anti-human pan T-cell (CD3) antibody (Dako Cytomation, Zug, Switzerland) 
and a monoclonal anti-human pan B-cell (CD79a) antibody (Dako Cytomation). 
 
Cloning and Expression of Canine Survivin 
Isolation of total RNA from Madin Darby Canine Kidney (MDCK) cells was performed 
with the RNeasy Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s 
protocols and as described previously (Keller et al., 2007b). Briefly, 40U Protector 
RNAse Inhibitor (Roche, Mannheim, Germany) were added to the extract. cDNA was 
synthesized from 1 µg of total RNA using the 1st strand cDNA Synthesis Kit for RT-PCR 
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(AMV) and an oligo-dT primer according to the manufacturer’s instructions (Roche).  
Amplification of the survivin open reading frame (ORF) was performed by PCR with 
primers survivinExUp (5’-ATGGGCGCTCGTCGCTG-3’) and survivinExDn (5’-
GAGCTATTCTGCGGCGGC-3’) using Platinum Taq DNA Polymerase High FidelityTM 
(Invitrogen, Carlsbad, California). PCR products were cloned into the glutathione S-
transferase (GST) pGEX-4T2 bacterial expression vector (GE Healthcare GmbH, 
Otelfingen, Switzerland) by sticky-end ligation. After transformation of the vector into 
Escherichia coli DH5α competent cells (Invitrogen AG, Basel, Switzerland), individual 
clones containing an insert of the expected size were sent for sequencing (Microsynth 
AG, Balgach, Switzerland).  The consensus sequence was derived from at least three 
different clones.  A clone containing the consensus survivin sequence was transformed 
into E. coli BL21Star competent cells for protein expression.  For expression of GST-
survivin and a GST protein only control, transformed cells containing either the survivin 
expression construct or empty vector were grown at 30 °C in 500 ml of lysogeny broth 
medium (LB) with 75 µg/ml ampicillin.  At an optical density of 0.6 at 600 nm, GST fusion 
protein expression was induced by the addition of 1 mM isopropyl-beta-D-
thiogalactopyranoside (IPTG, Sigma Aldrich Co., St. Louis, Missouri) with incubation 
under the same conditions for further 2.5 h. Thereafter the bacterial culture was 
processed for paraffin wax embedding, western blotting or antibody preincubation 
experiments. 
 
Western Blotting 
Following protein induction, bacterial cultures (1 ml) were centrifuged and the pellets 
were resuspended in 200 µl of 2x sodium dodecyl sulphate (SDS) buffer containing 10% 
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β-mercaptoethanol.  Samples were incubated at 95°C for 10 min, centrifuged for 5 min 
and 2 µl of bacterial lysates were loaded onto 12% SDS polyacrylamide gels and 
separated by gel electrophoresis (SDS-PAGE).  After transferring the proteins to a 
nitrocellulose membrane by means of a semi-dry blotting system (Biometra, Goettingen, 
Germany), non-specific antibody binding sites were blocked by incubation of the 
membrane for 1h at room temperature in Tris-buffered saline containing Tween 20 
0.05% (TBST) and bovine serum albumin (BSA) 3%.  The membrane was washed three 
times for 15 sec and twice for 10 min in TBST and then incubated for 1 h at room 
temperature with pSurv (1 µg/ml in BSA 1 %) or mSurv (2 µg/ml in BSA 1%). Following 
this initial incubation, the membranes were washed again with TBST as described above 
and incubated with secondary anti-mouse IgG conjugated to horseradish peroxidase 
(HRP; Geno Technologies, St Louis, Missouri) or anti-rabbit IgG conjugated to HRP 
(Jackson, ImmunoResearch, Soham, UK) diluted 1 in 10,000 for 1 h at room 
temperature in BSA 1%.  As a control for this analysis, the presence of GST-tagged 
proteins was detected using mouse anti-GST antibody (0.1 µg/ml) conjugated to HRP 
(Amersham Biosciences, Otelfingen, Switzerland). Signals were visualized following 
incubation with a LumiGloTM substrate (KPL, Maryland) and autoradiography.  
 
Keratinocyte Cultures 
Methods for culture, fixation and embedding of normal and neoplastic canine 
keratinocytes have been described previously (Keller et al., 2007b). Cells used included 
a normal canine keratinocyte line and a squamous cell carcinoma line (Crameri et al., 
1997; Keller et al., 2007b). 
 
 12 
Fixation and Embedding of Bacteria Expressing Recombinant Canine Protein  
100 ml cultures of E. coli BL21 cells, expressing GST-fusion proteins of survivin, XIAP 
(GenBank Accession number: DQ225116), cIAP1 (DQ223014), cIAP2 (EF102104), 
Smac/DIABLO (EF088670), Omi/HtrA2 (DQ138643) and GST alone, in addition to 
control E. coli MG1655 wild-type cells were centrifuged at 4,000 g for 10 min at 4°C and 
the pellets were resuspended in 4% neutral buffered formaldehyd and incubated for 24 h 
at room temperature. The cultures were subsequently centrifuged at 4,000 g for 10 min 
at room temperature. The resulting pellets were resuspended in 1.5 ml of 5% BSA in 
PBS plus 2 drops of hemalum in an Eppendorf tube before a final centrifugation at 4,000 
g at room temperature for 10 min. The pellets were embedded in paraffin wax with the 
Cytoblock system (Thermo Shandon, Pittsburgh, Pennsylvania).  
 
Tissue Array Construction 
Tissue arrays were constructed from archival samples by means of a manual tissue 
array production apparatus (Beecher Instruments, Sun Prairie, USA).  To minimize 
variation, all normal tissue and lymphoma samples used to assemble arrays were 
derived from patients that had been admitted to the Faculty clinic and all tissues had 
been fixed in house.  The majority of the specimens derived from biopsies.  The first 
array was composed of a broad spectrum of normal fetal and adult canine tissues (free 
of microscopical lesions) that had been fixed in 4% buffered formaldehyd for 24 to 48 h 
and embedded in paraffin wax.  Fetal tissues included placenta, kidney, liver, pancreas, 
lung, intestine, skeletal muscle, heart muscle and brain.  Adult tissues included placenta, 
kidney, liver, pancreas, spleen, lung, intestine, heart muscle, skeletal muscle, brain, 
testis and lymph node.  The array was constructed by collecting two cores of 1.2 mm 
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diameter (fetal tissues) or 0.6 mm diameter (adult tissues) from representative areas of 
each specimen that were transferred to paraffin wax recipient blocks (Micro-Cut Paraffin, 
Polysciences Inc., Warrington, USA).  Samples for each organ originated from two to 
three different individuals.  A further series of arrays was constructed using 95 samples 
of canine lymphoma (Keller et al., 2007a). Four cores of 0.6 mm diameter were collected 
from representative areas of each specimen.  Before sectioning, the blocks were 
immersed in water, kept at -20°C for 15 min, cut into sections of 1.5 µm and transferred 
to positively charged glass slides (Erie Scientific Company, Portsmouth, New 
Hampshire). 
 
Survivin Immunohistochemistry 
An optimized immunohistochemical procedure for detection of canine survivin was 
developed by testing a series of different antigen retrieval methods, primary antibody 
dilutions and incubation conditions (Keller et al., 2007b). The optimized conditions are 
described forthwith. Antigen retrieval was carried out for both anti-survivin antibodies by 
boiling the slides in Tris/ethylene diaminetetraacetic acid (EDTA) buffer pH 9 at 98°C for 
20 min in a pressure cooker (‘Pascal’; Dako Cytomation). The sections were cooled for 
10 min and then incubated with either pSurv (1 in 600 dilution or 1.6 µg/ml; 4oC 
overnight) or mSurv (1 in 10 dilution or 20 µg/ml; 1h at room temperature).  Peroxidase 
blocking solution (Dako Cytomation) was applied to the slides for 10 min at room 
temperature to inactivate endogenous peroxidase. The primary antibody was detected 
by use of a commercial kit (Dako REALTM Detection System, Dako Cytomation), 
according to the manufacturer’s instructions. Finally, a 3-amino-9ethylcarbazole (AEC) 
chromogen (Dako Cytomation) was applied to ‘visualize’ the reaction and the slides 
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were counterstained with hemalum and covered using KP-Tape (Klinipath, Duiven, The 
Netherlands).  IHC for bacterial pellets, normal and lymphoma tissues was performed on 
arrays, while IHC of pelleted cultured cells was performed on whole sections. 
Additionally, an antibody dilution series was tested with formalin-fixed paraffin wax-
embedded bacterial pellets to define the antibody titre (Keller et al., 2007b).  Labelling of 
normal tissues was scored according to intensity as (-) negative; (+/-) faint; (+) weak; 
(++) moderate; and (+++) strong.  Labelling of lymphoma tissues was scored by 
estimating the percentage of labelled cells. Prior to this evaluation, cores were checked 
to ensure that they were representative of the tumour by comparing B-cell and T-cell 
immunolabelling of consecutive sections with the results of immunophenotyping of the 
whole sections, and by comparing cellular morphology. Non-representative cores and 
cores containing prominent necrosis or autolytic change were excluded. Survivin 
expression was evaluated only in cases where at least one complete representative core 
was available.  
  
Preincubation of Antibodies 
The recombinant GST-survivin fusion protein and the GST protein alone expressed in 
bacterial cells were purified using gluthatione 4B sepharose beads (Amersham 
Biosciences), according to the manufacturer’s instructions and with minor modifications.  
Briefly, induced E. coli cultures (500 ml) were centrifuged and resuspended in lysis 
buffer (50 mM Tris-HCl, [pH 7.5], 1 % Triton X-100, 150 mM NaCl, 5 mM MgCl2, 1 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride and 10 µg Pepstatin A/ml) and 
lyzed by sonication.  625 µl sepharose beads were added to the supernatant and 
incubated for 1 h at 4 °C with mixing by inversion.  After washing, the beads were 
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resuspended in 2.1 ml lysis buffer and 2.9 ml 84% glycerol (50% final concentration) and 
separated into aliquots of 500 µl and stored at -20°C.  The purity of the protein and its 
concentration were determined using SDS-PAGE gels stained with Coomassie blue. 
Primary antibodies for survivin were diluted in commercial diluent (Dako REALTM) as 
described above to final concentrations of 1.6 µg/ml (pSurv) and 20 µg/ml (mSurv), 
respectively. Diluted primary antibodies and GST fusion protein-bound sepharose beads 
were incubated overnight at 4 °C, at a 10:1 antigen-antibody ratio, and mixed by 
inversion.  Following centrifugation of the bead solution, the preincubated antibody 
sample supernatant was stored at 4°C and used for IHC instead of the primary antibody 
where appropriate.  
 
Lymphoma Classification 
Lymphomas included in this study were classified using the original tissue sections and 
according to the revised Kiel classification adapted for the dog as previously described 
(Fournel-Fleury et al., 2002; Ponce et al., 2004) and by the Revised European American 
Lymphoma – World Health Organization (REAL-WHO) classification (Valli et al., 2002).  
The cases were immunophenotyped using sections from the original blocks (Keller et al., 
2007a). 
 
Results 
 
Cross-Reactivity of Antibodies with Recombinant Canine Survivin  
To establish a reliable method for the immunohistochemical detection of canine survivin, 
the cross-reactivity of the two anti-human primary antibodies was determined.  For this 
purpose, the entire coding sequence for survivin was cloned from MDCK cells. 
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Sequencing revealed 100% homology with the previously reported canine survivin 
reference sequence (GenBank Accession number NM_001003019). In western blotting 
with lysates of bacteria expressing canine recombinant proteins, both antibodies 
recognized a band of the expected molecular weight (43 kDa) corresponding to the 
GST-survivin fusion protein, while the reagents did not label GST alone (Figs. 1A – C).  
Both antibodies labelled formalin-fixed and paraffin wax-embedded bacteria expressing 
GST-survivin, but not bacteria expressing GST alone or other GST-tagged proteins 
including canine XIAP, cIAP1, cIAP2, Smac/DIABLO, or Omi/HtrA2, or normal E. coli 
(Figs. 1D and E), thus confirming the results of immunoblotting in a test system similar to 
the final application of this study.  The antibody titres, (i.e. the inverse of the highest 
antibody dilutions retaining a clear-cut difference in labelling between bacteria 
expressing the survivin fusion protein and bacteria expressing GST alone) were 2,500 
for pSurv and 40,000 for mSurv. 
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Fig. 1.  Cross-reactivity and specificity of 
commercially available anti-human survivin 
antibodies against canine survivin.  (A) 
Western blot detection of glutathione-S-transferase 
(GST, lane 1) and GST-survivin (lane 2) with anti-
GST antibody.  (B) GST and GST-survivin 
screened with pSurv.  (C) GST and GST-survivin 
incubated with mSurv.  (D)  Labelling of an array 
containing formalin-fixed, paraffin wax-embedded 
bacteria expressing GST or GST-fusion proteins as 
indicated, or normal E. coli (‘no vector’), each 
reaction in duplicate, with pSurv.  (E) Labelling of 
the same bacteria with mSurv.  XIAP, X-linked 
inhibitor of apoptosis protein; cIAP1, cellular 
inhibitor of apoptosis protein 1; cIAP2, cellular 
inhibitor of apoptosis protein 2; Smac/DIABLO, 
second mitochondria-derived activator of 
caspase/direct IAP-binding protein with low pI; 
Omi/HtrA2, Omi protease/high temperature 
requirement protein 2. 
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Immunohistochemical Detection of Survivin in Cultured Canine Keratinocytes 
After demonstrating cross-reactivity of the antibodies with the canine protein, 
immunohistochemical detection protocols for survivin were established with cultured 
canine cells. Both primary antibodies labelled formalin-fixed and paraffin wax-embedded 
cultured non-neoplastic (Fig. 2) and neoplastic (squamous cell carcinoma) keratinocytes 
(data not shown).  The labelling pattern was identical with both cell types and for each 
antibody and consisted of a predominantly multifocal cytoplasmic, finely granular signal 
visible in most of the cells, and a diffuse nuclear finely granular labelling present in 
approximately 50% of the cells.  Use of a polyclonal antibody potentially risks non-
specific labelling due to non-specific reactivity with unrelated antigens. To exclude this 
possibility, pSurv was preincubated with an excess of canine GST-survivin prior to 
incubation with consecutive sections of the cells.  Preincubation resulted in total loss of 
signal, suggesting that pSurv labelling is specific (Fig. 2).  The same preincubation 
procedure was performed with mSurv with similar results.  Preincubation of pSurv with 
GST alone lead only to a slight attenuation of the signal (data not shown). 
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Fig. 2. Immunohistochemical labelling of cultured normal canine keratinocytes.  pSurv and 
mSurv elicit a similar signal that is completely abrogated after preincubation with recombinant GST-canine 
survivin.  Labelling of cells with pSurv (A – B) and mSurv (C – D) without (A and C) and after (B and D) 
preincubation with GST-survivin. Bar, 20 µm. 
 
Survivin Expression in Normal Tissues 
The results of this investigation are summarized in Table 1 with representative images 
displayed in Fig. 3.  In both fetal and adult cells there was a predominant cytoplasmic 
expression of survivin.  Most positive cell types were labelled by both primary antibodies 
with the exception of neurons and primary spermatocytes in adult tissues, which were 
labelled only by pSurv.  Biliary ductal cells in adults, which were labelled with pSurv, 
were not available for labelling with mSurv because these structures were not 
represented in the section.  No tissue was labelled exclusively by the monoclonal  
 20 
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Fig. 3.  Immunohistochemical  labelling of normal adult dog tissues. (A – D) tissues labelled 
with  pSurv, (E – H) tissues labelled with mSurv; not preincubated, antibody not preincubated with 
recombinant canine survivin; preinc, antibody preincubated with recombinant canine survivin. (A) Placenta 
with granular cytoplasmic labelling of trophoblast and decidua cells.  (B) Skin with diffuse and granular 
cytoplasmic labelling of nucleated squamous epithelial cells.  The stratum corneum is unlabelled and the 
capillary endothelia are labelled.  (C) Lymph node tissue with predominantly unlabelled lymphocytes (left) 
and with labelled macrophages (middle).  (D) Brain tissue with granular cytoplasmic labelling of neurons.  
(E) Placenta with diffuse cytoplasmic labelling of trophoblast and decidua cells.  (F) Skin with diffuse faint 
cytoplasmic labelling of nucleated squamous epithelial cells and unlabelled stratum corneum.  (G) Lymph 
node tissue with predominantly unlabelled lymphocytes (left) and with labelled macrophages (middle).  (H) 
Intestine with diffuse cytoplasmic labelling of villus enterocytes and of scattered cells in the lamina propria.  
In all sections with preincubated antibody the signal is completely abrogated. Bar, 20 µm. 
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Table 1 
Immunohistochemical survivin detection in normal fetal and adult canine tissues 
  Immunohistochemical labeling result with indicated antibody 
Organ/tissue Cell type pSurv pSurv preinc mSurv mSurv preinc 
Intestine (F) Enterocytes (villi & crypts) ++ - + - 
 Lamina propria cells + - + - 
 Myocytes (Tunica muscularis) + - + - 
 Brunner's glandular cells - - - - 
Pancreas (F) Exocrine glandular cells ++ - + - 
 Exocrine ductal cells n.a. n.a. n.a. n.a. 
Brain (F) Neuronal cells - - - - 
 Glial cells ++ - + - 
 Ependymal cells + - + - 
Lung (F) Bronchiolar epithelial cells ++ - + - 
 Alveolar lining cells ++ - + - 
 Macrophages ++ - + - 
Liver  (F) Hepatocytes ++ - + - 
 Biliary epithelial cells n.a. n.a. n.a. n.a. 
Kidney (F) Tubular cells ++ - ++ - 
 Glomerular cells - - - - 
Placenta (F) Trophoblasts + - + - 
Heart (F) Myocytes + - + - 
Skeletal muscle (F) Myocytes + - + - 
      
Spleen (A) Lymphocytes - - - - 
 Plasma cells + - + - 
 Macrophages + - + - 
Intestine (A) Enterocytes (villi & crypts) + - + - 
 Lamina propria cells + - + - 
 Myocytes (Tunica muscularis) n.a. n.a. n.a. n.a. 
 Brunner's glandular cells - - - - 
Pancreas (A) Exocrine glandular cells ++ - + - 
 Exocrine ductal cells - - - - 
Brain (A) Neurons ++ - - - 
 Glial cells - - - - 
 Ependymal cells n.a. n.a. n.a. n.a. 
Lung (A) Bronchiolar epithelial cells - - - - 
 Alveolar lining cells - - - - 
 Macrophages - - - - 
Liver (A) Hepatocytes ++ +/- + - 
 Biliary epithelial cells ++ - n.a. n.a. 
Kidney (A) Tubular cells ++ +/- + - 
 Glomerular cells - - - - 
Placenta (A) Decidual cells + - + - 
Heart (A) Myocytes + - + - 
Skeletal muscle (A) Myocytes + - + - 
Testis (A) Leydig cells ++ - + - 
 Primary spermatocytes ++ - - - 
 Spermatids - - - - 
Skin (A) Squamous epithelial cells  ++ - + - 
 Hair follicle epithelial cells + - + - 
 Adnexal glandular cells +++ +/- ++ +/- 
Lymph node (A) Lymphocytes - - - - 
 Plasma cells ++ - ++ - 
 Macrophages ++ - ++ +/- 
(F), fetal.; (A), adult; pSurv = polyclonal rabbit anti-survivin antibody (Novus Biologicals); mSurv = mouse 
monoclonal anti-survivin antibody (Santa Cruz Biotechnology); preinc = indicated antibody preincubated 
with recombinant canine survivin; labelling intensity scoring: -, negative; +/- faint; +, weak; ++, moderate; 
and +++, strong; n.a. = not available; occasional, inconsistently observed labelling of vascular endothelial 
cells in several organs was not indicated. 
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antibody.  All positive cell types in fetal tissues were labelled by both antibodies.  In 
general, labelling with mSurv was less intense than with pSurv, except for placental 
tissue, which was more intensely labelled by the monoclonal antibody. Moreover, 
labelling with pSurv was generally diffusely homogeneous with superimposed fine 
granules, while most labelling with mSurv was diffusely homogeneous and labelled 
granules were rare. Preincubation of the primary antibodies with an excess of GST-
survivin resulted in complete loss of the signal in most tissues, supporting the notion that 
the labelling was specific for survivin.  In hepatocytes, renal tubular cells and cells of the 
cutaneous adnexal glands, weak residual labelling persisted after preincubation of pSurv 
antibody either in all cores (liver, skin) or in a portion of the cores examined (kidney).  
The same phenomenon was observed with mSurv for cells of the cutaneous adnexal 
glands and in macrophages in lymph nodes.  This residual reaction may have been due 
to the expression of unrelated cross-reacting antigens, incomplete depletion of specific 
antibodies during the preincubation step or the presence of antibodies not specific for 
survivin. 
In all lymphoid tissues included in the array, the majority of lymphocytes were 
unlabelled, while other cells, tentatively identified as plasma cells and cells of the 
reticuloendothelial system, showed cytoplasmic labelling. This was confirmed by 
labelling whole sections of two non-neoplastic canine lymph nodes.  In addition, 
examination of the whole sections revealed very faint nuclear staining of lymphocytes in 
the centre of some follicle, a finding that was not noted in the arrays due to the limited 
amount of tissue captured using this technique.  
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Survivin Expression in Canine Lymphoma 
Representative cores containing sufficient amounts of tumour tissue were available for 
83 of 95 tumours in the arrays labelled with pSurv and 82 of 95 tumours labelled with 
mSurv (Table 2).  In this analysis the most frequent tumour subtypes for each 
immunophenotype were reported separately and infrequent subtypes and cases that 
could not be classified were grouped together (other subtypes/not classifiable).  
Examples of signals detected with the two antibodies are shown in Fig. 4.  pSurv 
labelled a high proportion of neoplastic cells in all tumours.  The pattern of pSurv 
labelling was similar to that described for normal non-lymphoid tissues.  In general, the 
percentage of labelled tumour cells and the signal intensity were lower with mSurv.  
Nevertheless, mSurv labelled more than 5% of cells in 66 of 82 tumours and more than 
40% of cells in 51 of 82 tumours.  The labelling pattern for mSurv was predominantly 
cytoplasmic and diffuse. In all lymphoma tissues, labelling by both antibodies was 
completely lost following preincubation with survivin-GST.  
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Fig. 4.  Immunohistochemical labelling of canine lymphoma tissues. (A – B) Centroblastic 
monomorphic lymphoma (Kiel classification) / diffuse large B-cell lymphoma (REAL-WHO classification).  
(C – D) Centroblastic polymorphic lymphoma (Kiel classification) / diffuse large B-cell lymphoma (REAL-
WHO classification).  Labelling with pSurv (A and C) or mSurv (B and D). Bar,  20 µm. 
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Table 2 
Immunohistochemical detection of survivin in canine lymphomas 
Lymphoma subtype according to 
indicated classification scheme   
No. of tumours with indicated percentage of positive cells detected with indicated 
antibody 
Revised Kiel   REAL-WHO   pSurv   mSurv 
   
 
Total 
no. of 
case
s 
0-5% 6-39% 40-70% >70%  0-5% 6-39% 
40-
70% >70% 
B-Immunophenotype (n=45)  
          
centroblastic 
monomorphic 
 diffuse large B-cell  
 
7 0 0 1 6  1 1 1 4 
centroblastic 
polymorphic 
 diffuse large B-cell  
 
17 0 0 1 16  2 1 6 8 
marginal zone  marginal zone 
 
11 0 0 1 10  2 4 2 3 
other subtypes / not classifiable 
 
10 0 0 0 10  3 1 3 3 
              
T-Immunophenotype (n=28)  
          
pleomorphic 
(various 
sizes) 
 peripheral T-cell  not 
otherwise specified 
 
14 0 0 0 14  2 1 4 7 
large granular   blastic Natural Killer-
cell  
5* 0 0 0 5  1 3 0 0 
other subtypes / not classifiable 
 
9 0 0 0 9  1 2 1 5 
              
Double Negative-Immunophenotype 
(n=10)  
          
high-grade, 
medium sized 
  
 
4 0 0 0 4  1 0 1 2 
other subtypes / not classifiable 
 
6 0 0 1 5  3 2 0 1 
              
TOTAL   83* 0 0 4 79   16 15 18 33 
*  in one case tissue not available for analysis with mSurv; pSurv = polyclonal rabbit anti-survivin antibody 
(Novus Biologicals); mSurv = mouse monoclonal anti-survivin antibody (Santa Cruz Biotechnology). 
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Discussion 
 
The present study has examined immunohistochemically the expression of survivin in 
normal canine tissues and samples of lymphoma.  Reports of the expression of this 
protein in normal adult tissue vary (Andersen et al., 2007; Lechler et al., 2007; Altieri, 
2008).  The results of the present study indicate that cytoplasmic expression of survivin 
is widespread in normal fetal and adult canine tissues and that it is nearly ubiquitous 
across canine lymphoma subtypes.  In tumour cells, cytoplasmic expression of survivin 
has been suggested to contribute to tumorigenesis through its anti-apoptotic function 
(Stauber et al., 2007). 
The analysis of canine survivin expression was optimized by screening two 
commercially available human anti-survivin antibodies against recombinant canine 
survivin by a variety of methodologies.  IHC of paraffin wax-embedded bacteria allows 
exclusion of non-specific reactions with related proteins once the corresponding cDNAs 
are available.  The majority of immunohistochemical studies on human tissues report 
use of polyclonal antibodies for detection of survivin, and these are considered to be 
more sensitive than monoclonal antibodies (Grossman et al., 1999; Ding et al., 2006; 
Vischioni et al., 2007). The polyclonal antibody used in the present study has been used 
previously to label survivin in human specimens (Martinez et al., 2004; Schlette et al., 
2004;  Ding et al., 2006; Piras et al., 2007; Vischioni et al., 2007) as well as in canine 
mastocytoma, urinary bladder transitional cell carcinoma and lymphoma (Scase et al., 
2006; Rebhun et al., 2008; Velando Rankin et al., 2008).  In two of the latter studies 
(Scase et al., 2006; Rebhun et al., 2008), antibody specificity was confirmed by western 
blot analysis.  However, the quality of polyclonal antibodies may vary significantly 
between different batches and therefore it is advisable to test such antibodies whenever 
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possible before use (Keller et al., 2007b).  While most previous studies were based on 
the use of a single antibody, the present work confirmed labelling results obtained with 
the polyclonal antibody by application of the monoclonal antibody mSurv.  In general, 
there was high overall agreement in labeling by these two reagents with differences 
limited to a weaker signal intensity with mSurv. Since the range of organs showing 
signals and the reaction pattern were similar with both antibodies, the differences 
observed likely reflect the higher sensitivity of the polyclonal reagent. Similar findings 
have recently emerged in a detailed comparison of the labeling of human non-small cell 
lung carcinomas by the same two antibodies (Vischioni et al., 2007).  In that study both 
antibodies recognized both cytoplasmic and nuclear full length survivin as well as the 
alternatively spliced forms ΔEx3 and 2B ectopically expressed in a Human Breast 
adenocarcinoma cell line (MCF-7) cells. A possible explanation for rare discrepancies in 
labeling of certain cell types observed in the present study, including neurons in the 
brain and primary spermatocytes, may reside in the differential recognition of further 
alternatively spliced survivin isoforms or could derive from non-specific reactions. The 
latter were at least partially excluded by preincubation of the primary antibody with 
recombinant canine survivin as a negative control.  Overall, it would appear that pSurv is 
a reliable and sensitive tool for the detection of survivin in dog tissues.  
These antibodies identified widespread and predominantly cytoplasmic expression of 
survivin in normal canine fetal tissues as has been described for man and mouse 
(Ambrosini et al., 1997; Adida et al., 1998).  In contrast, it appears that survivin 
expression is more widespread in normal adult canine tissues than previously reported.  
The finding of survivin expression in epithelia of the placenta, gastrointestinal tract and 
skin are in agreement with multiple immunohistochemical studies of adult human and 
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rodent tissues (Chiodino et al., 1999; Gianani et al., 2001; Ding et al., 2006; Lechler et 
al., 2007; Piras et al., 2007) and with expression data available from a publicly 
accessible repository (http://www.proteinatlas.org/).  Positive expression in several 
further organs including testis, kidney, liver and brain ( Kobayashi et al., 1999; Altura et 
al., 2003; Moon and Tarnawski, 2003; Lechler et al., 2007) is supported by at least one 
previous study with human tissues and by data from the protein atlas.   One study in 
particular has demonstrated, with different methods, high survivin levels in the adult 
renal proximal tubules (Lechler et al., 2007).  Failure to report positivity of such organs in 
several other reports may relate from the fact that normal tissues were either not 
mentioned or not investigated in a cancer study, or from the use of different antibodies 
or IHC protocols.  Another reason may relate to individual variations in the expression of 
this protein.  For instance, in a recent study, cytoplasmic survivin labelling was detected 
in the epithelium in only 17 of 46 normal canine urinary bladders (Velando Rankin et al., 
2008).  Several additional tissues with reported positive cell types including oesophageal 
epithelium and bone marrow (Fukuda and Pelus, 2006) were not included in the present 
study but these tissues from dogs might also express survivin.   In the present study, a 
more extensive identification of cell types was not possible in the tissue microarrays due 
to the limited amount of tissue examined and the limited number of tissues included. 
Furthermore, the small number of individuals studied precludes assessment of individual 
variations.  However, the data point to widespread expression of survivin in normal adult 
canine tissues.  A more detailed study is warranted, particularly considering the fact that 
therapies targeting this molecule are currently under investigation in man and are not 
devoid of side effects (Altieri, 2008). 
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Previous reports indicate that survivin is frequently expressed in most cancer types 
(Andersen et al., 2007; Altieri, 2008).  The findings of the present study suggest that 
most, if not all, canine lymphomas express survivin and that this molecule might have a 
role in the genesis or maintenance of these tumours.  While pSurv consistently labelled 
most tumour cells in the majority of the cases analyzed, mSurv labelled fewer cells in a 
substantial number of tumours, suggesting differences in the level of expression 
between lymphomas.  In a recent report, a negative prognostic significance was 
ascribed to high levels of survivin expression assessed immunohistochemically in 
samples of canine B-cell lymphoma (Rebhun et al., 2008). In that study, survivin was 
detected in all tumour samples investigated, which is in accordance with our data based 
on a larger sample size.  Those authors did not report the relative extent of nuclear and 
cytoplasmic labelling, while in the present investigation cytoplasmic survivin appeared to 
be predominant.  In man, survivin is immunohistochemically detected in high grade 
rather than in low grade lymphomas, which are considered negative (Ambrosini et al., 
1997; Tracey et al., 2005).  In diffuse large B-cell lymphoma, survivin expression, 
detected by IHC, was reported in 43 – 80% of cases either in the nucleus (Watanuki-
Miyauchi et al., 2005; Liu et al., 2007), in the cytoplasm (Adida et al., 2000; Ambrosini et 
al., 1997) or without mention of subcellular localization (Tracey et al., 2005).  In mantle 
cell lymphoma, another subtype of B-cell lymphoma, survivin expression was reported to 
be rare (Tracey et al., 2005), while another report described mean expression of 10 –  
30% of tumour cells with dominant nuclear labelling (Martinez et al., 2004). Importantly, 
this latter study, in which pSurv was used, confirmed subcellular localization by western 
blotting of lysates of tumour cell lines and of tumour cells isolated from patients and 
subjected to subcellular fractionation.  Another group, using the same antibody, 
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identified cytoplasmic survivin expression in 55% of anaplastic large-cell lymphomas (a 
subtype of lymphoma mostly comprising T-cells) and confirmed the subcellular 
localization in cell lines (Schlette et al., 2004).  In contrast to these studies in man, both 
the present investigation and a previous study point to widespread expression of survivin 
across most subtypes of canine lymphoma (Rebhun et al., 2008). 
In conclusion, by application of a combination of two different antibodies against survivin 
and screening of arrays of normal tissue, the present study has shown widespread 
cytoplasmic survivin expression in normal adult canine tissues.  These observations 
should be taken into account when developing therapies targeting this molecule for the 
management of neoplastic disease. 
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